Improving radical treatment through MRI evaluation of pelvic sigmoid cancers 

IMPRESS is a two group Phase II randomized interventional clinical trial of the use of high resolution MRI for identifying and treating poor prognosis sigmoid cancers. Patients with pelvic sigmoid cancer in the randomised arm will be randomized to either CT (control arm and standard of care) or investigational MRI (next to standard CT) preoperative staging.

The IMPRESS trial is open to new sites.

Please fill in the form below if you would like further information or have any questions about any aspect of the trial.